2025 Preliminary Full Year Result (Unaudited)

Results announcement

1


IPERION LIMITED

Results for announcement to the market
Name of issuer Iperion Limited (NZX: IPR)
Reporting Period 12 months to 31 March 2025
Previous Reporting Period 12 months to 31 March 2024
Currency NZD
Amount (000s) Percentage change
Revenue from continuing
operations
$0 0%
Total Revenue $0 0%
Net profit/(loss) from
continuing operations
$(444) (46%)
Total net profit/(loss) $(444) (46%)
Interim/Final Dividend
Amount per Quoted Equity
Security
The company does not propose to pay a dividend at this time.
Imputed amount per Quoted
Equity Security
Not applicable
Record Date Not applicable
Dividend Payment Date Not applicable
Current period Prior comparable period
Net tangible assets per Quoted
Equity Security
$0.001 $0.002
A brief explanation of any of
the figures above necessary to
enable the figures to be
understood
Included with this report is the commentary from the Directors and
financial statements for the year ended 31 March 2025.
The financial statements are in the process of being audited.
Authority for this announcement
Name of person authorised to
make this announcement
John Cilliers
Contact person for this
announcement
John Cilliers
Contact phone number +6 27 242 8485
Contact email address john.cilliers@outlook.co.nz
Date of release through MAP 29 May 2025

2

IPERION LIMITED

Preliminary Full Year Result for the Year Ended 31 March 2025.

Dear Shareholders

The Directors of Iperion Limited (“the Company”) are pleased to report its financial results for the
year ended 31 March 2025.

Financial Results
The Company reported a net loss attributable to shareholders of $444,433 for the year. This
compares with a net loss attributable to shareholders of $822,259 for the previous year.

The manufacturing plant expense for the year was $150,000. This is significantly less than the
$500,000 incurred in the prior year. The prior year consisted of $100,000 for the establishment of
the manufacturing facility and $400,000 for the fixed annual facility and operating fees. The
Company received a discount of $350,000 on the fixed fee for the 2025 year in recognition of lower
than expected production activity and the plant being partially supported by research grants secured
by the Operator, Three Summit Ventures, on the ongoing development in applications for the
Pathoglaze® product.
Three Summit Ventures has also agreed to fully discount the agreed $400,000 fixed fee for the next
financial year ending March 2026. Fees required to support direct production costs may still be
payable when sales activities commence.

Administrative expenses for the year were $306,531 decreasing by $47,841 on the prior year.
Expenses remained mostly in line with the previous year, except for stock exchange costs that were
lower this year and the previous year included higher costs for international trade fairs.

Operations
Operations continue to be focused on completing product trials applying Pathoglaze in various
applications, undertaken in response to and in collaboration with potential large multinational
commercial customers interested in applying Pathoglaze in their own products manufacturing
processes. Possible applications for Pathoglaze previously successfully tested, includes antimicrobial
coatings for furniture and egg cartons, kitchen chopping boards, applied to textiles to make odour
combating clothing, or mixed in plastics used in the automotive industry or in food containers to
make them antimicrobial and as a coating on curtains to reduce microbes in hospitals. Recent trials
completed include manufacture of bags used in shipping cocoa and coffee beans, reducing microbial
contamination and associated losses incurred during transport, providing a new alternative to the
standard bags currently used in these industries.

The Company continues to work toward securing long term sales agreements.

Having completed various product trials the focus of the company is on marketing activities and
converting the product trials undertaken with potential customers into long term sales agreements.
Based on approved base case forecasts with no sales, the Company has sufficient cash reserves to
cover its costs over the next 12 months.
On behalf of the Directors of Iperion the Company extends its thanks to the shareholders for their
support of the Company.

3



Preliminary Statement of Comprehensive Income
For the year ended 31 March 2025
Unaudited
Audited
Year
Year
2025
2024
$
$
Outsourced manufacturing plant expenses
(150,000)


(500,000)


Interest Income - financial asset at amortised cost
20,382


41,396


Administrative expenses
(306,531)


(354,372)


Depreciation, amortisation and impairment
(8,284)


(9,283)


(444,433)


(822,259)


Finance costs
-


-


Loss before income tax
(444,433)


(822,259)


Income tax expense
-


-


Net loss for the period attributable to shareholders
(444,433)


(822,259)


Other comprehensive income
-


-


(444,433)


(822,259)


Loss before interest and tax
Total comprehensive loss for the period attributable to shareholders

4




Preliminary Statement of Financial Position
As at 31 March 2025
Unaudited
Audited
Year
Year
2025
2024
$
$
Assets
Current assets
Cash and cash equivalents
425,341


168,647


Term Deposit
-


697,834


GST receivable
1,384


-


Income tax receivable (RWT)
7,563


12,030


434,288


878,511


Non-current assets
NZX Deposit
20,000


20,000


20,000


20,000


Total assets
454,288


898,511


Equity and liabilities
Current liabilities
Trade and other payables
94,640


93,105


GST payable
-


1,325


Total liabilities
94,640


94,430


Equity
Issued capital
5,672,856


5,672,856


Accumulated loss
(5,313,208)


(4,868,775)


Total equity
359,648


804,081


Total equity and liabilities
454,288


898,511

5


Preliminary Statement of Changes in Equity
For the year ended 31 March 2025
Issued
capital
Accumulated
Loss
Total equity
$
$
$
As at 1 April 2024
5,672,856


(4,868,775)


804,081


Loss for the year
-


(444,433)


(444,433)


Total comprehensive income
-


(444,433)


(444,433)


At 31 March 2025
5,672,856


(5,313,208)


359,648


As at 1 April 2023
5,672,856


(4,046,516)


1,626,340


Loss for the year
-


(822,259)


(822,259)


Total comprehensive income
-


(822,259)


(822,259)


At 31 March 2024
5,672,856


(4,868,775)


804,081


Unaudited

6



Preliminary Statement of Cash Flows
For the year ended 31 March 2025
Unaudited
Audted
Year
Year
2025
2024
$
$
Operating activities
13,622


41,479


Payments to suppliers
(479,839)


(782,103)


Net GST refunds received
22,134


22,134


Income tax paid
(7,563)


(12,030)


Income tax refund received
12,030


5,766


Net cash flows from operating activities
(439,616)


(724,754)


Investing activities
Purchase of intangible assets
(8,284)


(9,283)


704,594


520,571


Net cash flows from investing activities
696,310


511,288


Net increase / (decrease) in cash and cash equivalents
256,694


(213,466)


Cash and cash equivalents at beginning of year
168,647


382,113


Cash and cash equivalents at end of year
425,341


168,647


Interest received
Cash received from maturity of term deposit